Search Results
Nov 06, 2025, 08:00 ET OncoHost Wins 'Proteomics Innovation of the Year' at the BioTech Breakthrough Awards
of proteins are profiled and analyzed with proprietary AI models, generating patient-specific predictive scores for both progression-free survival (PFS) and overall survival (OS). The PROphet® proteomic signature has also demonstrated predictive value across melanoma, renal cell carcinoma (RCC), HPV-associated
More news about: OncoHost
Nov 06, 2025, 07:00 ET Mark Cuban Cost Plus Drug Company Expands Access with Addition of Starjemza® (ustekinumab-hmny) to Give Patients More Power Over Prescription Costs
Starjemza® will be listed at a starting price of $345 per quarter (plus shipping) for the 90 mg/mL pre-filled syringe (PFS). Additional configurations, including the 45 mg/mL and 130 mg/mL PFS, will also be offered and priced in accordance with the company's transparent cost-plus model.
More news about: Mark Cuban Cost Plus Drug Company
Nov 05, 2025, 16:05 ET Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance
ES-SCLC based on positive data from the Phase 3 IMforte trial. Top-line PFS data from zanidatamab in Phase 3 1L GEA expected in 4Q25; updated intent-to-treat population for PFS to include all patients enrolled in the trial. Narrowed 2025 total revenue
More news about: Jazz Pharmaceuticals plc
Nov 05, 2025, 16:05 ET Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance
ES-SCLC based on positive data from the Phase 3 IMforte trial. Top-line PFS data from zanidatamab in Phase 3 1L GEA expected in 4Q25; updated intent-to-treat population for PFS to include all patients enrolled in the trial. Narrowed 2025 total revenue
More news about: Jazz Pharmaceuticals plc
Nov 04, 2025, 09:01 ET AI-Powered Spatial Biology Workflow from Bio-Techne and Nucleai Enables Predictive Biomarker Discovery in Melanoma Patients
high-plex imaging, histopathology, and clinical outcome data to identify distinct immune cell interactions that correlate with progression-free survival (PFS), overall survival (OS), and clinical benefit across three treatment arms incorporating Immune Checkpoint Blockade (ICB).
More news about: Bio-Techne Corporation
Nov 04, 2025, 08:32 ET iLeukon Receives FDA Clearance of IND Application for A Phase II Study of mRNA-based non-alpha IL-2 variant, ILKN421H, in Advanced Non-Small Cell Lung Cancer (NSCLC)
first-line NSCLC, achieved a confirmed objective response rate (ORR) of 80% (n=16/20) regardless of PD-L1 expression, with median progression-free survival (PFS) not yet reached and projected to exceed 12 months. The summary of this Phase I study was selected as an oral presentation at the upcoming SITC Annual
More news about: iLeukon Therapeutics
Nov 04, 2025, 07:30 ET Actinium Pharmaceuticals, Inc. to Highlight ATNM-400 Data in Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Expanding Pan-Tumor Profile Across Three Solid Tumor Indications
Clinical rationale for combination supported by a study that showed EBRT or external-beam radiotherapy + osimertinib improved PFS to 32.2 months vs. 20 months with osimertinib alone (Sampath et al.1, Lancet eClinicalMedicine, 2025). ATNM-400 has the potential to
More news about: Actinium Pharmaceuticals, Inc.
Nov 04, 2025, 06:00 ET IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
combination in 1L HLA*A2-negative metastatic uveal melanoma (mUM) to report median PFS data by year-end 2025 to 1Q 2026; on track to complete enrollment by year-end 21.1 month median OS and 7.0 month median PFS reported from single-arm Phase 2 trial (OptimUM-01) evaluating the darovasertib/crizotinib
More news about: IDEAYA Biosciences, Inc.
Nov 03, 2025, 19:06 ET Energy Fuels Announces Q3-2025 Results
50,000 tonnes per annum ("tpa") of monazite, producing approximately 5,000 tpa of NdPr, 150 to 225 tpa of Dy, and 50 to 75 tpa of Tb. The Mill PFS referenced above can be viewed on the Company's website,
More news about: Energy Fuels Inc.
Nov 03, 2025, 08:00 ET Servier Announces Positive Findings from Longer-Term Analysis of the Phase 3 INDIGO Trial Showing Continued Durable Treatment Effect of VORANIGO® (vorasidenib) Published in The Lancet Oncology
Median progression-free survival (PFS) improved with VORANIGO (not estimable [NE] [95% CI, 22.1-NE]) compared to placebo (11.4 [95% CI, 11.1-13.9] months), with the hazard ratio (HR) continuing to favor VORANIGO (HR, 0.35 [95% CI, 0.25-0.49]; p<0.0001*). PFS was the primary endpoint of the trial.
More news about: Servier Pharmaceuticals
Nov 03, 2025, 07:15 ET ADC Therapeutics to Host Third Quarter 2025 Financial Results Conference Call on November 10, 2025
consistent with or different from the LOTIS-7 data presented at EHA and ICML and future compendia and regulatory strategy and opportunity; the timing of the PFS events for LOTIS-5 and the results of the trial and full FDA approval; the Company's ability to grow ZYNLONTA® revenue in the United States and potential
More news about: ADC Therapeutics SA
Nov 02, 2025, 23:12 ET Akeso's Ivonescimab Secures Fourth Breakthrough Therapy Designation in China for First-Line Treatment of Triple-Negative Breast Cancer
first final OS analysis in a Phase III trial of ivonescimab, these results reaffirm the agent's groundbreaking value in both progression-free survival (PFS) and overall survival for patients. Moreover, a head-to-head Phase III trial comparing ivonescimab plus chemotherapy to tislelizumab plus chemotherapy
More news about: Akeso, Inc.
Oct 30, 2025, 10:59 ET First Dual-Positive Immunotherapy with PFS and OS Benefit in EGFR+ NSCLC After EGFR-TKI Progression: Ivonescimab Final OS Analysis from HARMONi-A to Be Presented at SITC 2025
EGFR-TKI-resistant, EGFR-mutated non-squamous NSCLC to show statistically significant and clinically meaningful improvements in both progression-free survival (PFS) and overall survival (OS). This marks ivonescimab's first final OS analysis in a Phase III trial and confirms its groundbreaking survival benefit for
More news about: Akeso, Inc.
Oct 30, 2025, 08:00 ET ARIS MINING ANNOUNCES APPOINTMENT OF BRIGITTE BAPTISTE TO THE BOARD
Marmato Complex, expected to start ramping up production in H2 2026. In addition, Aris Mining operates the 51% owned Soto Norte joint venture, where a PFS study is complete on a new, smaller scale development plan which confirms Soto Norte as a high-quality, long-life project with robust economics and industry-leading
More news about: Aris Mining Corporation
Oct 30, 2025, 07:00 ET Hot Chili Quarterly Report Period Ending 30 September, 2025
and exclusions. The PFS Technical Report is intended to be read as a whole, and sections should not be read or relied upon out of context. The technical information in this report is subject to the assumptions and qualifications to be contained in the PFS Technical Report. The PFS Technical Report replaces
More news about: Hot Chili Limited
Oct 29, 2025, 17:30 ET ARIS MINING REPORTS Q3 2025 RESULTS
Prefeasibility Study (PFS) completed in September 2025, demonstrating robust economics with, on a 100% basis, after-tax NPV5% of $2.7 billion, IRR of 35%, and 2.3-year
More news about: Aris Mining Corporation
Oct 28, 2025, 17:30 ET ARIS MINING ANNOUNCES POSITIVE PEA RESULTS FOR THE TOROPARU GOLD PROJECT
major technical study this year, following the Soto Norte Prefeasibility Study (PFS) in September, and together they demonstrate the strength of our growth pipeline beyond Segovia and Marmato. Aris Mining has initiated a PFS for Toroparu, targeted for completion in 2026, with the objective of advancing
More news about: Aris Mining Corporation
Oct 27, 2025, 14:23 ET YY Group公布2025年增長戰略：聚焦全球勞動力解決方案與IFM業務拓展
Circle今年已進駐3個新市場，目前海外業務約佔其用工總收入的45%。受益於內部數字營銷能力的增強，截至2025年6月30日，該平台新增企業客戶超80家，註冊勞動力規模較去年同期增加約12.2萬人。 IFM業務收購：2025年2月，YY Group收購了Property Facility Services Pte. Ltd.（「PFS」），為其設施管理服務整合策略奠定了基礎。隨後，該公司於2025年6月收購了Uniforce Security Pte. Ltd.和24IFM（原Managing Facilities Applications），並於2025年7月收購了Pesticide Pest Control Pte. Ltd.，大幅拓寬了其IFM服務組合和收入來源。
More news about: YY Group Holding Limited
Oct 27, 2025, 13:01 ET Three Cord True Wealth Management Unveils New Website for Better Client Communication
clarity at every step so successful families and business owners can make informed decisions with confidence," said Tod Arbutina, CPA, CFP®, MBA, CKA®, PFS. "The new site reflects our listen‑first, deeply customized approach and makes it easier to engage our team, access resources, and move from uncertainty
More news about: Three Cord True Wealth Management
Oct 27, 2025, 09:00 ET Financial Industry Veteran Sheryl Rowling Launches New Practice, Offering Highly Personalized Tax and Financial Planning for Individuals and Advisory Firms
Oct. 27, 2025 /PRNewswire/ -- Sheryl Rowling, a distinguished Certified Public Accountant (CPA) and Personal Financial Specialist (PFS), today announced the launch of her firm, Sheryl Rowling CPA Accountancy Corporation. The firm will provide a comprehensive suite of tax and financial
More news about: Sheryl Rowling CPA Accountancy Corporation
Oct 27, 2025, 08:30 ET YY Group Outlines 2025 Growth Strategy Featuring Global Workforce Solutions and IFM Expansion
2025. IFM Acquisitions: In February 2025, YY Group acquired Property Facility Services Pte. Ltd. ("PFS"), laying the groundwork for the Company's consolidated approach to facility management services. Since then, the Company has broadened its IFM service
More news about: YY Group Holding Limited
Oct 27, 2025, 07:15 ET ADC Therapeutics to Present at November Investor Conferences
consistent with or different from the LOTIS-7 data presented at EHA and ICML and future regulatory and compendia strategy and opportunity; the timing of the PFS events for LOTIS-5 and the results of the trial and full FDA approval for ZYNLONTA®; future safety and efficacy results of the Phase 2 IIT in MZL and
More news about: ADC Therapeutics SA
Oct 27, 2025, 07:00 ET Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
In addition, previously published data of external beam radiotherapy (EBRT) combined with osimertinib resulted in improved progression free survival (PFS) compared to osimertinib alone, providing a strong clinical rationale for combining targeted alpha-therapy via ATNM-400 with EGFR targeting therapies Sampath
More news about: Actinium Pharmaceuticals, Inc.
Oct 27, 2025, 06:00 ET West Synchrony™ Prefillable Syringe System Launches at CPHI: Redefining a system-level solution for drug delivery
Key benefits of the West Synchrony PFS system include: Design and System-Level Performance: a single design verification and characterization package from West ensures the form, fit and function of the entire PFS system. Regulatory
More news about: West Pharmaceutical Services, Inc.
Oct 23, 2025, 18:54 ET Defense Metals Appoints Ali Mahdavi as SVP Corporate Development, and grants incentive stock options
the port facilities at Prince Rupert, the closest major North American port to Asia. The Company recently completed a Preliminary Feasibility Study (PFS) that demonstrated the robust economics of the project. For further information, please visit
More news about: Defense Metals Corp.